By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Boehringer Ingelheim Pharma GmbH & Co. KG et al. v. Barr Laboratories Inc. et al.
1:07-cv-00432; filed July 11, 2007 in the District Court of Delaware
Infringement of U.S. Patent No. 6,015,577 ("Pharmaceutical Compositions Containing Dipyridamole or Mopidamol and Acetylsalicylic Acid or the Physiologically Acceptable Salts Thereof, Processes for Preparing Them and Their Use in Treating Clot Formation," issued January 18, 2000) following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Boehringer's Aggrenox® (extended-release dipyridamole/acetylsalicylic acid, used to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis). View the complaint here.
Wyeth v. Mylan Pharmaceuticals Inc.
1:07-cv-00091; filed July 9, 2007 in the Northern District of West Virginia
Infringement of U.S. Patent Nos. 6,274,171 ("Extended release formulation of venlafaxine hydrochloride," issued August 14, 2001), 6,403,120 (same title, issued June 11, 2002), and 6,419,958 (same title, issued July 16, 2002) following a paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Wyeth's EFFEXOR XR® (venlafaxine hydrochloride, extended release, used to treat depression). View the complaint here.
Sanofi-Aventis U.S. LLC et al. v. Actavis Totowa LLC et al.
3:07-cv-03142; filed July 6, 2007 in the District Court of New Jersey
Sanofi-Aventis U.S. LLC et al. v. Pharmachemie B.V. et al.
3:07-cv-03144; filed July 6, 2007 in the District Court of New Jersey
Sanofi-Aventis U.S. LLC et al. v. Abraxis Bioscience, Inc.
3:07-cv-03163; filed July 9, 2007 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 5,338,874 ("Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) Having Optically High Purity," issued August 16, 1994) following a paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of plaintiffs' Eloxatin® (oxaliplatin for injection, used to treat colorectal cancer). View the Actavis complaint here.
Sanofi-Aventis U.S. LLC et al. v. Mustafa Nevzat Ilac Sanayh A.S. et al.
3:07-cv-03143; filed July 6, 2007 in the District Court of New Jersey
Sanofi-Aventis U.S. LLC et al. v. Ebewe Pharma GES M.B.H. NFG.KG
3:07-cv-03164; filed July 9, 2007 in the District Court of New Jersey
Sanofi-Aventis US LLC et al. v. Ebewe Pharma GES M.B.H. NFG.KG
3:07-cv-01756; filed July 10, 2007 in the District Court of South Carolina
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 5,338,874 ("Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) Having Optically High Purity," issued August 16, 1994) and 5,716,988 ("Pharmaceutically Stable Preparation of Oxaliplatinum," issued February 10, 1998) following a paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of plaintiffs' Eloxatin® (oxaliplatin for injection, used to treat colorectal cancer). View the Mustafa complaint here.
Comments